Final data presented from the Phase 2 SHASTA-2 trial of the GalNAc-conjugated, siRNA, plozasiran, in 229 patients with severe hypertriglyceridaemia (SHTG) have confirmed that treatment significantly reduced levels of TG, apoC3 and remnant cholesterol,1 with results published simultaneously in JAMA Cardiology.2